Microcap Ledger Minerva Neurosciences, Inc. $NERV
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Burlington, MA
- Fiscal year end
- December 31
- Shares outstanding
- 47,747,559 [10-Q 2026-08-07]
What the company doesAI summary of filing
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing proprietary product candidates to treat central nervous system diseases. The company's lead product, roluperidone, is in Phase 3 development for negative symptoms in schizophrenia patients; the company submitted a New Drug Application to the FDA in August 2022 but received a Complete Response Letter in February 2024 and is planning a confirmatory Phase 3 trial expected to begin in the second quarter of 2026. The company has not generated revenue from product sales and has accumulated significant losses since inception, with an accumulated deficit of $688.8 million as of December 31, 2025. Minerva previously co-developed seltorexant with Janssen for insomnia and major depressive disorder but sold its royalty rights to Royalty Pharma in January 2021 for $60 million upfront plus up to $95 million in potential milestone payments. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$107.94M | −$18.77M | $24.65M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | — | −$293.42M | −$13.51M | $82.30M | [DEF 14A 2026-04-23] |
| FY ended Dec 2024 | $0.00 | $1.44M | −$19.55M | $21.36M | [10-K 2025-02-25] |
- Quarterly cash burn
- −$9.39M
- Cash runway Estimate
- ~7.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-02-20 | 6,993,406 | [10-K 2025-02-25] |
| 2025-04-18 | 6,993,406 | [10-K/A 2025-04-29] |
| 2025-05-08 | 6,993,406 | [10-Q 2025-05-13] |
| 2025-08-08 | 6,993,406 | [10-Q 2025-08-14] |
| 2025-10-31 | 6,993,406 | [10-Q 2025-11-05] |
| 2026-03-06 | 43,274,398 | [10-K 2026-03-11] |
| 2026-04-30 | 46,588,709 | [10-Q 2026-05-05] |
| 2026-08-04 | 47,747,559 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-03-11; declared effective 2026-03-19 [S-3 2026-03-11]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-10-11. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-10-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Director or officer change |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-07 | 8-K | Results of operations |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-04 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-27 | 8-K | Material agreement entered; Other events |
| 2026-05-27 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-05 | 10-Q | Quarterly report |
Alerts for $NERV
Email me when Minerva Neurosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.